$REGN 8-K SEC Filings

Filed On	Filing
06 Oct 2026	8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron” or the “Company”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“Sanofi Biotechnology”), and Sanofi...
30 Sep 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Plan: Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan
30 Jul 2026	8-K: Results of Operations and Financial Condition
06 Jul 2026	8-K: Results of Operations and Financial Condition
17 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
29 Apr 2026	8-K: Results of Operations and Financial Condition
08 Apr 2026	8-K: Results of Operations and Financial Condition
30 Jan 2026	8-K: Results of Operations and Financial Condition
12 Jan 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
28 Oct 2025	8-K: Results of Operations and Financial Condition
06 Oct 2025	8-K: Results of Operations and Financial Condition
01 Aug 2025	8-K: Results of Operations and Financial Condition
18 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
29 Apr 2025	8-K: Results of Operations and Financial Condition
04 Feb 2025	8-K: Results of Operations and Financial Condition; Other Events
13 Jan 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
31 Oct 2024	8-K: Results of Operations and Financial Condition
07 Oct 2024	8-K: Results of Operations and Financial Condition
01 Aug 2024	8-K: Results of Operations and Financial Condition
08 Jul 2024	8-K: Results of Operations and Financial Condition

Comments